Ablynx, Boehringer Ingelheim deal

Ablynx and Boehringer extended by two years through September 2014 a 2007 deal to use Ablynx's Nanobody technology to discover, develop and commercialize up to 10 therapeutic proteins against undisclosed targets to treat cancer, and immunological and respiratory diseases. Ablynx will receive €6.6 million ($8.7 million) in additional research funding. Ablynx said the extended deal will allow the programs to advance to in vitro testing after which Boehringer is responsible for further development and commercialization. Ablynx said two programs have advanced to preclinical testing (see BioCentury, Sept. 10, 2007). ...